Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 47 min ago
Peer-reviewedCC BY 4.0Cancers

Immunotherapies and Chemo-Sparing Approaches: A New Era for Diffuse Large B-Cell Lymphoma in Older Patients

  • Filippo Fasano1
  • Bianca Patarnello1
  • Claudia Marinucci2
  • Matteo Bisio1
  • Luca Legato1
  • Barbara Botto1
  • Michele Clerico2
  • Roberto Freilone1
  • Mattia Novo1
  1. 1Division of Hematology, A.O.U. Città Della Salute e Della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy
  2. 2Division of University Hematology, A.O.U. Città Della Salute e Della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy
Open at sourceDOICite

Abstract

Older patients with diffuse large B-cell lymphoma (DLBCL) represent a particularly challenging population. Reduced-dose rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-miniCHOP) can cure approximately half of patients; however, those who fail frontline therapy or are ineligible for anthracycline-based regimens have historically been considered to have a dismal prognosis. Nevertheless, over the past few years, several effective salvage immunotherapies have been introduced into clinical practice, including naked monoclonal antibodies, such as tafasitamab, antibody–drug conjugates, such as polatuzumab vedotin, and loncastuximab tesirine, and CD20 × CD3 bispecific antibodies (BsAbs). Moreover, novel combined approaches are currently under investigation as frontline therapy, such as the triplets polatuzumab vedotin plus rituximab and glofitamab (Pola-R-Glo), and tafasitamab plus lenalidomide and rituximab (TLR), or the upfront use of single-agent CD20 × CD3 BsAbs. These strategies aim to spare toxicity in older and frail patients and have shown promising efficacy, potentially heralding a chemo-free era for DLBCL in the older in the near future.

Related

  1. Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort.
    Changgon Kim, Youngil Koh, Youngwoo Jeon +4
    Annals of hematologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCPMC
  2. Analysis of Treatment Patterns and Outcomes Among Patients with Third-Line or Later (3L+) Diffuse Large B-Cell Lymphoma (DLBCL) with Multiple Qualifying Index Dates Treated in the United States.
    Michael Wallington, Yong Chen, Fei Jie +9
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCCrossref
  3. Associations of Subcutaneous and Visceral Fat Areas with Progression-Free Survival in Patients with Diffuse Large B-Cell Lymphoma.
    Jiun-Hung Geng, Chien-Hsiang Chang, Yi-Chang Liu +9
    International journal of medical sciencesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. PREDICTIVE VALUE OF INTEGRATING CIRCULATING TUMOR DNA AND END-OF-TREATMENT PET/CT FOR RELAPSE PREDICTION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED AT A REFERRAL CENTER
    Christopher CRALCEV, Guilherme DUFFLES, Jersey Heitor Silva MAUÉS +8
    Hematology, Transfusion and Cell TherapyPeer-reviewedCC BYFull textEndocrinology & metabolismDOAJ
  5. SOLUBLE CELL ADHESION MOLECULES QUANTIFICATION IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: PROGNOSTIC IMPLICATIONS AND CLINICAL-BIOLOGICAL ASSOCIATIONS
    Paola Carolina RABESQUINI MARCELINO DA SILVA, Igor CEREJO TAVARES DA SILVA DE ALMEIDA, Joaquim GASPARINI DOS SANTOS +7
    Hematology, Transfusion and Cell TherapyPeer-reviewedCC BYFull textEndocrinology & metabolismDOAJ

Cite

BibTeXRIS
BibTeX
@article{fasano2026immunotherapies,
  title = {{Immunotherapies and Chemo-Sparing Approaches: A New Era for Diffuse Large B-Cell Lymphoma in Older Patients}},
  author = {Filippo Fasano and Bianca Patarnello and Claudia Marinucci and Matteo Bisio and Luca Legato and Barbara Botto and Michele Clerico and Roberto Freilone and Mattia Novo},
  journal = {Cancers},
  year = {2026},
  month = nov,
  doi = {10.3390/cancers18213584},
  url = {https://www.mdpi.com/2072-6694/18/21/3584},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Immunotherapies and Chemo-Sparing Approaches: A New Era for Diffuse Large B-Cell Lymphoma in Older Patients
AU  - Filippo Fasano
AU  - Bianca Patarnello
AU  - Claudia Marinucci
AU  - Matteo Bisio
AU  - Luca Legato
AU  - Barbara Botto
AU  - Michele Clerico
AU  - Roberto Freilone
AU  - Mattia Novo
PY  - 2026
DA  - 2026/11/07
JO  - Cancers
DO  - 10.3390/cancers18213584
UR  - https://www.mdpi.com/2072-6694/18/21/3584
AB  - Older patients with diffuse large B-cell lymphoma (DLBCL) represent a particularly challenging population. Reduced-dose rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-miniCHOP) can cure approximately half of patients; however, those who fail frontline therapy or are ineligible for anthracycline-based regimens have historically been considered to have a dismal prognosis. Nevertheless, over the past few years, several effective salvage immunotherapies have been introduced into clinical practice, including naked monoclonal antibodies, such as tafasitamab, antibody–drug conjugates, such as polatuzumab vedotin, and loncastuximab tesirine, and CD20 × CD3 bispecific antibodies (BsAbs). Moreover, novel combined approaches are currently under investigation as frontline therapy, such as the triplets polatuzumab vedotin plus rituximab and glofitamab (Pola-R-Glo), and tafasitamab plus lenalidomide and rituximab (TLR), or the upfront use of single-agent CD20 × CD3 BsAbs. These strategies aim to spare toxicity in older and frail patients and have shown promising efficacy, potentially heralding a chemo-free era for DLBCL in the older in the near future.
SN  - 2072-6694
ER  -